-
Wanbangde New Building Materials’ Mecobalamin Earns FDA Orphan Drug Designation for ALS
•
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) announced that its mecobalamin product has received an orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for the treatment of amyotrophic lateral sclerosis (ALS). The designation highlights the drug’s potential to address unmet medical needs in ALS,…
-
Wanbangde’s Huperzine A Receives FDA Clearance for HIE Study
•
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced receiving clearance from the US Food and Drug Administration (FDA) to study its huperzine A in neonatal hypoxic-ischemic encephalopathy (HIE). This indication has earned the drug a rare pediatric disease (RPD) designation and orphan drug designation (ODD) from the…
-
Wepon Medical’s WP107 Receives FDA Approval for gMG Clinical Trial
•
China-based Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced receiving clinical trial approval from the US Food and Drug Administration (FDA) for its in-house developed WP107 (huperzine A). The acetylcholinesterase inhibitor is slated to enter a clinical study for the treatment of generalized myasthenia gravis (gMG). WP107: Preclinical…
-
Wepon Medical’s WP107 for Myasthenia Gravis Accepted for FDA Review
•
Wepon Medical Holding Group Co., Ltd. (SHE: 002082) has announced that the US Food and Drug Administration (FDA) has accepted its clinical filing for WP107 (huperzine A), an in-house developed drug, for review. The drug is intended to treat generalized myasthenia gravis (gMG), a serious neuromuscular disorder. WP107: A Promising…
-
Wanbangde’s Huperzine A Earns Orphan Drug Status from FDA for Treating Neonatal Brain Injury
•
Wanbangde New Building Materials Co., Ltd (SHE: 002082), a company operating in China, has announced that its drug candidate, huperzine A, has been granted an orphan drug designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE). This designation is a significant…
-
Wanbangde Pharmaceutical’s Huperzine A Earns FDA Rare Pediatric Disease Designation for HIE Treatment
•
China’s Wanbangde New Building Materials Co., Ltd (SHE: 002082) has announced that its subsidiary, Wanbangde Pharmaceutical Group, has received a rare pediatric disease (RPD) designation from the US Food and Drug Administration (FDA) for its drug huperzine A. This designation is for the treatment of neonatal hypoxic-ischemic encephalopathy (HIE), a…
